ATE430751T1 - Thienopyridinderivate als allostere gaba-b- enhancer - Google Patents

Thienopyridinderivate als allostere gaba-b- enhancer

Info

Publication number
ATE430751T1
ATE430751T1 AT05815262T AT05815262T ATE430751T1 AT E430751 T1 ATE430751 T1 AT E430751T1 AT 05815262 T AT05815262 T AT 05815262T AT 05815262 T AT05815262 T AT 05815262T AT E430751 T1 ATE430751 T1 AT E430751T1
Authority
AT
Austria
Prior art keywords
allostere
gaba
enhancers
thienopyridine derivatives
thienopyridine
Prior art date
Application number
AT05815262T
Other languages
English (en)
Inventor
Parichehr Malherbe
Raffaello Masciadri
Roger Norcross
Hasane Ratni
Andrew Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE430751T1 publication Critical patent/ATE430751T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT05815262T 2004-12-17 2005-12-09 Thienopyridinderivate als allostere gaba-b- enhancer ATE430751T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106665 2004-12-17
PCT/EP2005/013194 WO2006063732A1 (en) 2004-12-17 2005-12-09 Thieno-pyridine derivatives as gaba-b allosteric enhancers

Publications (1)

Publication Number Publication Date
ATE430751T1 true ATE430751T1 (de) 2009-05-15

Family

ID=35702999

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05815262T ATE430751T1 (de) 2004-12-17 2005-12-09 Thienopyridinderivate als allostere gaba-b- enhancer

Country Status (17)

Country Link
US (1) US7390903B2 (de)
EP (1) EP1828199B1 (de)
JP (1) JP2008524134A (de)
KR (1) KR100912145B1 (de)
CN (1) CN101120003B (de)
AR (1) AR051995A1 (de)
AT (1) ATE430751T1 (de)
AU (1) AU2005315937A1 (de)
BR (1) BRPI0519521A2 (de)
CA (1) CA2591211A1 (de)
DE (1) DE602005014383D1 (de)
ES (1) ES2324231T3 (de)
MX (1) MX2007007026A (de)
PL (1) PL1828199T3 (de)
RU (1) RU2388761C2 (de)
TW (1) TW200633708A (de)
WO (1) WO2006063732A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
AU2013202912B2 (en) * 2007-06-08 2016-10-27 Firmenich Incorporated Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) * 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
MX2011001155A (es) 2008-07-31 2011-07-29 Senomyx Inc Composiciones que comprenden mejoradores del dulzor, y métodos para prepararlas.
EP3085699B1 (de) 2008-07-31 2022-03-02 Firmenich Incorporated Verfahren zur herstellung von verstärkern des süssen geschmacks
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
ES2753523T3 (es) 2010-04-02 2020-04-13 Firmenich Incorporated Modificador del sabor dulce
CN103153096B (zh) 2010-08-12 2016-08-03 赛诺米克斯公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
CA2817896A1 (en) * 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
PH12014500184A1 (en) 2011-08-12 2014-03-24 Firmenich Incorporated Sweet flavor modifier
CN104093722B (zh) * 2012-02-09 2016-07-27 默克专利股份公司 作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
AU2013299859B2 (en) 2012-08-06 2017-06-15 Firmenich Incorporated Sweet flavor modifier
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
EA201690089A1 (ru) 2013-06-11 2017-04-28 Латвийский Институт Органического Синтеза ТИЕНО[2,3-b]ПИРИДИНЫ КАК МОДУЛЯТОРЫ СОСТОЯНИЯ МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
TWI648281B (zh) * 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
CA2963901A1 (en) 2014-11-07 2016-05-12 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers
JP7097623B2 (ja) * 2016-11-07 2022-07-08 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
WO2020033420A1 (en) 2018-08-07 2020-02-13 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
CN109081846A (zh) * 2018-10-08 2018-12-25 浙江工业大学上虞研究院有限公司 4-氨基噻吩[2,3-b]吡啶类化合物的制备方法
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414192D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414199D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel Compounds
GB202414200D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1003419A (en) * 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
GB8801491D0 (en) * 1988-01-22 1988-02-24 Beecham Group Plc Novel compounds
GB8804448D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8921304D0 (en) * 1989-09-20 1989-11-08 Wyeth John & Brother Ltd New method of treatment and heterocyclic compounds used therein
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
JPH07500831A (ja) * 1991-11-07 1995-01-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｃｎｓ活性テトラヒドロベンゾチエノピリジン
WO1996014319A1 (en) * 1994-11-08 1996-05-17 Takeda Chemical Industries, Ltd. Thienopyridine or thienopyrimidine derivatives and their use
FR2800072B1 (fr) * 1999-10-22 2002-01-11 Centre Nat Rech Scient 1-(2-butyrolactones et 2-thiobutyrolactones)-isoquinolines n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et dans le traitement des troubles nerveux et leur procede de preparation
AU2001234420A1 (en) 2000-02-03 2001-08-14 Eli Lilly And Company Potentiators of glutamate receptors
TW591031B (en) * 2000-02-29 2004-06-11 Takeda Chemical Industries Ltd Thienopyridine derivatives, their production and use
US6559163B2 (en) * 2000-08-16 2003-05-06 Neurogen Corporation 2,4-substituted quinoline derivatives
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7390903B2 (en) 2008-06-24
JP2008524134A (ja) 2008-07-10
US20060135552A1 (en) 2006-06-22
MX2007007026A (es) 2007-07-04
BRPI0519521A2 (pt) 2009-02-10
KR100912145B1 (ko) 2009-08-14
RU2007121908A (ru) 2009-01-27
KR20070091016A (ko) 2007-09-06
TW200633708A (en) 2006-10-01
AR051995A1 (es) 2007-02-21
DE602005014383D1 (en) 2009-06-18
CA2591211A1 (en) 2006-06-22
AU2005315937A1 (en) 2006-06-22
WO2006063732A1 (en) 2006-06-22
PL1828199T3 (pl) 2009-10-30
CN101120003B (zh) 2010-06-16
RU2388761C2 (ru) 2010-05-10
EP1828199B1 (de) 2009-05-06
CN101120003A (zh) 2008-02-06
ES2324231T3 (es) 2009-08-03
EP1828199A1 (de) 2007-09-05

Similar Documents

Publication Publication Date Title
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
ATE509627T1 (de) Zusammensetzungen mit nebivolol
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
ATE501138T1 (de) Thiophenderivate als chk-1-inhibitoren
EP1788047A4 (de) Wasserabweisende/ölabweisende zusammensetzung
ATE394399T1 (de) Tetrahydropyridoindolderivate
PL1828199T3 (pl) Pochodne tieno-pirydyny jako alosteryczne wzmacniacze gaba-b
ATE540935T1 (de) Chinazolinderivate
DK1761541T3 (da) Pyrrazolo-pyrimidin-derivater
ATE512960T1 (de) Pyrimidinderivate
DK1804871T3 (da) Forbedret mellemstykke
ATE417830T1 (de) Sulfonylbenzimidazolderivate
DE602005020768D1 (de) Flammfestes kunstleder
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE602005008986D1 (de) Substituierte hydantoine
ATE396724T1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
IL187425A0 (en) 3-methanesulfonylquinolines as gaba-b enhancers
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
FI20040071A0 (fi) Kytkinlaitemoduuli
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1828199

Country of ref document: EP